Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sapropterin dihydrochloride oral suspension - APR Applied Pharma Research

Next Previous
Drug Profile

Sapropterin dihydrochloride oral suspension - APR Applied Pharma Research

Alternative Names: APR-OD032; RLF-OD032

Latest Information Update: 29 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Meta Healthcare
  • Developer RELIEF THERAPEUTICS Holding
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Phenylketonuria

Most Recent Events

  • 23 May 2025 APR Applied Pharma Research plans a phase I bioequivalence trial in Healthy volunteers (PO, Suspension), in June 2025 (NCT06987773)
  • 25 Oct 2024 Meta Healthcare files provisional patent applications for RLF OD032 with the United States Patent and Trademark Office (US PTO)
  • 25 Oct 2024 Relief Therapeutics announces intention to submit NDA to US FDA for Phenylketonuria (unspecified) in the third quarter of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top